Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2014 2
2015 4
2016 4
2018 3
2019 3
2020 2
2021 7
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Lecocq Q, et al. Among authors: goyvaerts c. Theranostics. 2019 Oct 15;9(25):7772-7791. doi: 10.7150/thno.34941. eCollection 2019. Theranostics. 2019. PMID: 31695800 Free PMC article. Review.
Cancer-Associated Myeloid Regulatory Cells.
De Vlaeminck Y, González-Rascón A, Goyvaerts C, Breckpot K. De Vlaeminck Y, et al. Among authors: goyvaerts c. Front Immunol. 2016 Mar 29;7:113. doi: 10.3389/fimmu.2016.00113. eCollection 2016. Front Immunol. 2016. PMID: 27065074 Free PMC article. Review.
Editorial: Rising stars in cancer immunity and immunotherapy 2022.
Goyvaerts C, Engeland CE, Van der Jeught K. Goyvaerts C, et al. Front Immunol. 2023 Nov 7;14:1326374. doi: 10.3389/fimmu.2023.1326374. eCollection 2023. Front Immunol. 2023. PMID: 38022618 Free PMC article. No abstract available.
Towards a personalized iPSC-based vaccine.
Goyvaerts C, Breckpot K. Goyvaerts C, et al. Nat Biomed Eng. 2018 May;2(5):277-278. doi: 10.1038/s41551-018-0237-7. Nat Biomed Eng. 2018. PMID: 30936451 No abstract available.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: goyvaerts c. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
Targeting the tumor microenvironment to enhance antitumor immune responses.
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Van der Jeught K, et al. Among authors: goyvaerts c. Oncotarget. 2015 Jan 30;6(3):1359-81. doi: 10.18632/oncotarget.3204. Oncotarget. 2015. PMID: 25682197 Free PMC article. Review.
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, Mey W, Lecocq Q, Vlaeminck Y, Awad RM, Goyvaerts C, Veirman K, Morgenstern A, Bruchertseifer F, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K. Ertveldt T, et al. Among authors: goyvaerts c. J Nucl Med. 2023 May;64(5):751-758. doi: 10.2967/jnumed.122.264752. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055223
38 results